The California NanoSystems Institute (CNSI) at UCLA today announced a partnership with the integrated global biopharmaceutical company Abraxis BioScience Inc. to collaborate on nanobiotechnology research for the advancement of new technologies in medicine.
Abraxis BioScience will collaborate with the institute and its team of leading researchers to capitalize on the recent explosion in nanoscience and to chart the future of nanotechnology within biotechnology. Abraxis has agreed to contribute $10 million over 10 years to fund collaborative projects at UCLAs new CNSI building. The Abraxis/CNSI Research Collaboration Lab will focus on translational science, quickly translating scientific discoveries into practical applications.
Abraxis BioScience has joined the CNSI Partners Program and is the institutes first partner in the area of pharmaceuticals and biotechnology. The partnership provides CNSI and Abraxis researchers the opportunity to jointly pursue innovative approaches to the diagnosis and treatment of life threatening diseases, leveraging the complementary resources and skills of both organizations. To further support the partnership, visiting scholars from other institutions will also participate in the collaborative research programs.
We are eager to collaborate with Abraxis BioScience. Cross-disciplinary collaboration is vital to our research efforts, said Fraser Stoddart, CNSI director and UCLAs Fred Kavli Professor of Nanosystems Sciences. The exciting thing about nanosystems research is that it is bringing about a sea change in the academic environment it is breaking down the barriers between disciplines to achieve a seamless integration between chemistry, physics, biology and engineering in all of their different forms.
We are very excited about this research collaboration with the CNSI and believe this type of relationship emphasizes our commitment toward pursuing innovative research and forging new paradigms
Contact: Jennifer Marcus
University of California - Los Angeles